#1 Clinical Trials Search in Europe

CHOLINE ALFOSCERATE

Choline alfoscerate (also called alpha-glyceryl phosphoryl choline or Gliatilin®) is a drug being studied for its potential benefits in various neurological conditions. This article examines clinical trials investigating choline alfoscerate’s effects on cognitive impairment following stroke, vascular cognitive impairment, and depression with memory complaints in older adults. These trials aim to determine whether this cholinergic precursor can improve cognitive functions like memory, attention, and executive functioning in patients with these conditions. The studies generally compare choline alfoscerate to placebo or evaluate it in combination with other medications to assess its effectiveness and safety profile.

Table of Contents

What is Choline Alfoscerate?

Choline alfoscerate, also known as alpha-glyceryl phosphoryl choline or alpha-GPC, is a medication used to treat various cognitive disorders. It is marketed under several brand names including Gliatilin® and Delecit[1][2]. This compound serves as a cholinergic precursor, which means it helps the body produce acetylcholine, an important neurotransmitter (chemical messenger) in the brain that plays a key role in memory and cognitive function.

How Choline Alfoscerate Works

Choline alfoscerate works by providing a source of choline to the brain. When it enters the body, it crosses the blood-brain barrier (a protective boundary that prevents many substances from reaching the brain) and is converted into acetylcholine. This neurotransmitter is crucial for proper communication between nerve cells and plays a significant role in memory, attention, and cognitive functions[1].

Research indicates that patients with certain cognitive disorders, including vascular cognitive impairment (cognitive problems related to blood vessel disease in the brain), often have deficits in brain cholinergic neurotransmission[2]. By increasing the availability of acetylcholine, choline alfoscerate aims to improve these cognitive functions.

Medical Conditions Treated with Choline Alfoscerate

According to the clinical trials reviewed, choline alfoscerate is primarily investigated for treating several neurological and psychiatric conditions[1][2][3][4]:

  • Vascular Cognitive Impairment (VCI) – A spectrum of cognitive disorders related to cerebrovascular diseases
  • Post-stroke cognitive deficits – Cognitive problems that occur after a stroke
  • Major Depression with subjective memory complaints – In older adults who experience both depression and memory issues

Vascular Cognitive Impairment

Vascular Cognitive Impairment (VCI) encompasses a range of cognitive disorders related to blood vessel diseases in the brain. It can range from mild cognitive impairment to more severe dementia. Currently, there are no approved treatments specifically for VCI, and the main therapeutic approaches focus on controlling vascular risk factors to prevent development or progression[2].

Several studies have found cholinergic deficits (problems with the acetylcholine system) in the brains of patients with VCI. Choline alfoscerate is being studied for its potential to address these deficits and improve cognitive function in these patients[1].

One clinical trial is investigating whether a combination of choline alfoscerate (1200mg per day) and nimodipine (a calcium channel blocker that affects blood vessels) is more effective than nimodipine alone in reducing cognitive decline in patients with subcortical VCI[2]. This approach targets both the cholinergic deficit and the vascular component of the disease.

Post-Stroke Cognitive Recovery

Stroke can cause significant cognitive impairment, affecting a person’s memory, attention, and other cognitive functions. Research suggests that choline alfoscerate may help improve cognitive function in post-stroke patients[1][4].

One study is examining the effectiveness of choline alfoscerate compared to placebo in improving cognition in post-stroke patients with Vascular Cognitive Impairment-No Dementia (VCI-ND). This condition refers to cognitive problems related to vascular issues that are not severe enough to be classified as dementia[1].

Another clinical trial is using Navigated Brain Stimulation (NBS) to evaluate the effect of different neuroprotective drugs, including choline alfoscerate, on motor centers and tracts after ischemic stroke. This approach allows researchers to measure the electrical activity in the brain more precisely than traditional clinical scales, potentially offering a more sensitive way to detect improvements[4].

Depression with Memory Complaints

Older adults with Major Depressive Disorder (MDD) often experience subjective memory complaints, which can significantly impact their quality of life. A clinical trial is investigating whether choline alfoscerate can improve symptoms related to depression, anxiety, and subjective memory complaints in patients over the age of 60 who have MDD and subjective cognitive decline[3].

In this study, participants receive choline alfoscerate as an adjunctive therapy (added to their regular antidepressant medication). The researchers are evaluating improvements in memory function, depression, anxiety, and satisfaction with medication over an 8-week period[3].

Dosage Information

Based on the clinical trials reviewed, choline alfoscerate is administered in various dosages depending on the condition being treated[1][2][3][4]:

  • For Vascular Cognitive Impairment: 400mg three times a day (1200mg total daily dose) for 12 weeks[1] or 600mg twice daily (1200mg total) in combination with nimodipine[2]
  • For Depression with Memory Complaints: 400mg twice daily[3]
  • For Post-Stroke Recovery: 1000mg daily intravenously (IV) for 10 days[4]

The medication may be administered orally (by mouth) as tablets or intravenously, depending on the specific treatment protocol and the patient’s condition[4].

Clinical Evidence and Effectiveness

Several clinical studies have investigated the effects of choline alfoscerate on cognitive function. According to one review mentioned in the trial information, a comparison of the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) results showed a more positive trend with choline alfoscerate than with certain cholinesterase inhibitors (another class of drugs used for cognitive disorders)[1].

The effectiveness of choline alfoscerate is being measured using various assessment tools in the clinical trials, including[1][2][3]:

  • Korean Trail Making Test (K-TMT-e) – Assesses visual attention and task switching
  • Montreal Cognitive Assessment (MoCA) – A rapid screening instrument for mild cognitive dysfunction
  • Color Word Stroop Test (CWST) – Measures selective attention
  • Trail Making Test (TMT) – Evaluates visual attention and task switching
  • Symbol Digit Modalities Test (SDMT) – Assesses cognitive functioning
  • Rey Auditory-Verbal Learning Test (RAVLT) – Assesses verbal learning and memory
  • Korean version of Perceived Deficits Questionnaire-Depression – Measures subjective cognitive complaints in depression
  • Motor Evoked Potential (MEP) parameters – Measures brain electrical activity related to motor function

The results of these ongoing clinical trials will provide more evidence about the effectiveness of choline alfoscerate for different cognitive conditions[1][2][3][4].

Side Effects and Safety

The clinical trials are assessing the safety and tolerability of choline alfoscerate as part of their secondary outcomes[2][3]. While specific side effects are not detailed in the trial summaries, the studies are monitoring for adverse events.

In general, medications that affect the cholinergic system may cause side effects such as gastrointestinal issues (nausea, vomiting, diarrhea), increased sweating, and changes in heart rate or blood pressure. However, the specific side effect profile of choline alfoscerate should be discussed with a healthcare provider.

The double-blind, placebo-controlled design of these studies will help determine whether any side effects are specifically related to choline alfoscerate or might occur with equal frequency in patients taking a placebo[1][2][3].

Trial ID Focus Treatment Regimen Duration Primary Outcome Measure
NCT01363648 Post-stroke patients with Vascular Cognitive Impairment no Dementia (VCI-ND) Choline alfoscerate 400mg, three times daily vs placebo 12 weeks Change in Korean Trail Making Test (K-TMT-e A) of K-VCIHS-NP
NCT03228498 Subcortical Vascular Cognitive Impairment Choline alfoscerate 1200mg/day (600mg twice daily) plus nimodipine 90mg/day vs nimodipine plus placebo 12 months Cognitive decline measured by Montreal Cognitive Assessment (MoCA) test
NCT05257902 Older adults (60+) with Major Depression and subjective memory complaints Choline alfoscerate 400mg twice daily as adjunctive therapy with antidepressants vs placebo 8 weeks Change in total score of Korean Perceived Deficits Questionnaire-Depression
NCT01388738 Neuroprotection after ischemic stroke Choline alfoscerate IV 1000mg daily vs cerebrolysin vs citicoline 10 days Motor evoked potential parameters: threshold, latency, amplitude

FAQ

  • What is choline alfoscerate and how does it work? Choline alfoscerate (also known as alpha-glyceryl phosphoryl choline) is a precursor to acetylcholine, an important neurotransmitter in the brain. It works by potentially increasing acetylcholine levels, which are often reduced in conditions affecting cognitive function. This mechanism may help improve brain functions related to memory, attention, and thinking abilities. The drug is being studied for its potential to enhance cholinergic neurotransmission, which plays a key role in cognitive processes.
  • What conditions are being treated with choline alfoscerate in these clinical trials? The clinical trials are investigating choline alfoscerate for several conditions: vascular cognitive impairment after stroke (without dementia), subcortical vascular cognitive impairment, major depression with subjective memory complaints in older adults (over 60 years), and as a neuroprotective agent following ischemic stroke. These studies focus on patients who have cognitive deficits resulting from reduced blood flow to the brain or depression-related memory issues.
  • What dosages of choline alfoscerate are being used in these trials? The dosages vary across trials. Some studies use 1200mg per day (divided as 400mg three times daily or 600mg twice daily), while others use 1000mg administered intravenously. One trial specifically examined choline alfoscerate at 400mg twice daily as an add-on therapy for depression. The appropriate dosage appears to depend on the specific condition being treated and the administration method (oral versus intravenous).
  • How is effectiveness measured in these choline alfoscerate trials? Effectiveness is measured using various cognitive and functional assessments. For cognitive function, tests include the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and specialized tests for attention and memory like the Trail Making Test. For depression studies, scales include the Hamilton Rating Scale for Depression and the Geriatric Depression Scale. Some trials also use more advanced techniques like Motor Evoked Potentials (MEPs) to measure changes in brain function. Patient-reported outcomes regarding memory complaints and medication satisfaction are also evaluated.
  • Is choline alfoscerate being studied alone or in combination with other treatments? Choline alfoscerate is being studied both alone and in combination with other treatments. In some trials, it's compared directly to placebo to assess its independent effects. In others, it's used as an add-on therapy alongside existing treatments, such as with antidepressants in older adults with depression, or in combination with nimodipine (a calcium channel blocker) for vascular cognitive impairment. These combination approaches aim to determine if choline alfoscerate can enhance outcomes when used with other medications.

Ongoing Clinical Trials on CHOLINE ALFOSCERATE

  • Study on the Effectiveness of Choline Alfoscerate for Treating Mild Depression in Elderly Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Choline Alfoscerate for Patients with Mild Cognitive Impairment

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Italy

Glossary

  • Vascular Cognitive Impairment (VCI): A broad term that describes a range of cognitive problems caused by or associated with vascular disease (problems with blood vessels). It ranges from mild cognitive problems to more severe dementia and is often caused by reduced blood flow to the brain or small vessel disease.
  • Choline Alfoscerate: A cholinergic precursor drug (also called alpha-glyceryl phosphoryl choline) that may increase levels of acetylcholine in the brain. It's being studied for its potential to improve cognitive functions in various neurological conditions.
  • Cholinergic: Relating to nerve cells or fibers that use acetylcholine as their neurotransmitter. The cholinergic system plays an important role in memory, attention, and other cognitive functions.
  • Acetylcholine: A neurotransmitter (chemical messenger) in the brain that is important for memory, attention, and muscle movement. Levels of acetylcholine are often reduced in conditions affecting cognitive function.
  • Montreal Cognitive Assessment (MoCA): A screening test designed to detect mild cognitive impairment. It assesses different cognitive domains including attention, memory, language, and orientation. A decrease of 2 or more points may indicate cognitive decline.
  • Mini-Mental State Examination (MMSE): A 30-point questionnaire used to measure cognitive impairment. It tests orientation, registration, attention and calculation, recall, and language abilities.
  • Ischemic Stroke: A type of stroke caused by a blockage in a blood vessel supplying blood to the brain, resulting in damage to brain tissue due to lack of oxygen and nutrients.
  • Subjective Memory Complaints: Self-reported problems with memory that may not be detectable on standard cognitive tests but are concerning to the individual experiencing them.
  • Navigated Brain Stimulation (NBS): A technique that uses magnetic pulses to stimulate specific areas of the brain while navigating with brain imaging. It can be used to map brain functions and assess brain pathways.
  • Motor Evoked Potential (MEP): An electrical response recorded from muscles following stimulation of the brain. MEPs can be used to evaluate the integrity of the motor pathways from the brain to the muscles.
  • Leukoaraiosis: Changes in the white matter of the brain seen on brain scans that appear as bright white areas. These changes are associated with small vessel disease and can contribute to cognitive impairment.
  • Hamilton Rating Scale for Depression (HAM-D): A multiple-item questionnaire used to provide an indication of depression and as a guide to evaluate recovery. Higher scores indicate more severe depression.
  • Small Vessel Disease: A condition affecting the small blood vessels in the brain, which can lead to reduced blood flow and damage to brain tissue, potentially causing cognitive impairment.
  • Double-blind Study: A research study in which neither the participants nor the researchers know which participants are receiving the experimental treatment and which are receiving a placebo or standard treatment.
  • Placebo: An inactive substance that looks like the drug being tested but has no therapeutic effect. It's used as a control in clinical trials to test the effectiveness of medications.

References

  1. https://clinicaltrials.gov/study/NCT01363648
  2. https://clinicaltrials.gov/study/NCT03228498
  3. https://clinicaltrials.gov/study/NCT05257902
  4. https://clinicaltrials.gov/study/NCT01388738